Stockwatch: Will Earnings Season Rescue The Sector?
This article was originally published in Scrip
Executive Summary
At the end of last week, snowfalls and blizzards engulfing the East Coast brought not just an early end to the working week and the first positive weekly stock market close of the year, but a weather system that postponed my trip to New York City and Philadelphia. It will probably take more than the optimism engendered by an early start to last weekend to reverse the dismal year-to-date performance of life science stocks. That would take a positive earnings season.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.